Cancer Immunology, Immunotherapy

, Volume 30, Issue 1, pp 43–50 | Cite as

Biological characterization of a chimeric mouse-human IgM antibody directed against the 17-1A antigen

  • William E. Fogler
  • Lee K. Sun
  • Mark R. Klinger
  • John Ghrayeb
  • Peter E. Daddona
Original articles


A chimeric antibody was constructed in which the murine H- and L-chain variable regions of mAb 17-1A, raised against human colorectal cancer cells, were joined with the human constant μ and κ regions. Transfection of these constructs into the murine myeloma Sp2/0 resulted in the expression and secretion of a pentameric Ig, designated chimeric 17-1A IgM. The chimeric 17-1A IgM was subsequently compared to a previously described chimeric 17-1A IgG1 for biological activities. Both chimeric mAbs were equally effective (weight basis) in competing against the binding of murine125I-17-1A to cultures of HT-29 colon carcinoma cells. The calculated association constants for the chimeric 17-1A IgM and IgG1 were 1.63 × 108 1/mol and 3.41 × 107 1/mol, respectively. Unlike chimeric 17-1A IgG1, the chimeric 17-1A IgM was able to render colon carcinoma target cells susceptible to lysis by both xenogeneic (rabbit) and human complement. The extent of complement-mediated lysis dependent upon chimeric 17-1A IgM was correlated to 17-1A antigen expression on target cells. HT-29 colon carcinoma cells treated with chimeric 17-1A IgM did not directly result in antibody-dependent cellular cytotoxicity by human peripheral blood monocytes. However, chimeric 17-1A IgM greatly enhanced the deposition of C3 on complementtreated HT-29 cells, and concomitant incubation with monocytes resulted in heightened lysis of the tumor cells. The feasibility of enhancing host defense against gastrointestinal malignancies by the administration of this chimeric 17-1A IgM may have certain clinical advantages.


Colon Carcinoma Colorectal Cancer Cell Peripheral Blood Monocyte Human Colorectal Cancer Biological Characterization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bara S, Lint TS (1987) The third component of complement (C3) bound to tumor target cells enhances their sensitivity to killing by activated macrophages. J Immunol 138: 1303Google Scholar
  2. 2.
    Brown BA, Davis GL, Saltzgaber-Muller J, Simon P, Ho M, Shaw PS, Stone BA, Sands H, Moore GP (1987) Tumor-specific genetically engineered murine/human chimeric monoclonal antibody. Cancer Res 47: 3577Google Scholar
  3. 3.
    Carney DF, Koski CL, Shin ML (1985) Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. J Immunol 134: 1804Google Scholar
  4. 4.
    Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach JF (1986) Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 137: 830Google Scholar
  5. 5.
    Cheung NV, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME (1988) Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 81: 1122Google Scholar
  6. 6.
    Del Vecchio S, Carrasquillo JA, Steis R, Bookman M, Smith J, Reynolds J, Perentesis P, McCabe R, Hanna MG, Haspel MV, Longo D, Larson SM (1987) Imaging of colon cancer with I-131 28A32 human monoclonal antibody. J Nucl Med 28: 636Google Scholar
  7. 7.
    Dillman RO (1987) Antibody therapy. In: Principles of cancer biotherapy. Raven Press, New York, NY, p 291Google Scholar
  8. 8.
    Fogler WE, Klinger MR, Abraham KG, Gottlinger HG, Riethmuller G, Daddona PE (1988) Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen. Cancer Res 48: 6303Google Scholar
  9. 9.
    Freundlich B, Avdalovic N (1983) Use of gelatin/plasma coated flasks for isolating human peripheral blood monocytes. J Immunol Methods 62: 31Google Scholar
  10. 10.
    Gomez F, Kelley M, Rossman MD, Dauber J, Schreiber AD (1982) Macrophage recognition of complement coated lymphoblastoid cells. J Reticuloendothel Soc 31: 241Google Scholar
  11. 11.
    Herlyn D, Herlyn M, Steplewski Z, Koprowski H (1979) Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol 9: 657Google Scholar
  12. 12.
    Herlyn M, Steplewski Z, Herlyn D, Koprowski H (1979) Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76: 1438Google Scholar
  13. 13.
    Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H (1980) Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 40: 717Google Scholar
  14. 14.
    Herlyn D, Herlyn M, Steplewski Z, Koprowski H (1985) Monoclonal antihuman tumor antibodies of six isotopes in cytotoxic reactions with human and murine effector cells. Cell Immunol 92: 105Google Scholar
  15. 15.
    Jolley ME, Wang C-HJ, Ekenberg SJ, Zuelke MS, Kelso DM (1984) Particle concentration fluorescence immunoassay (PCFIA): a new, rapid immunoassay technique with high sensitivity. J Immunol Methods 67: 21Google Scholar
  16. 16.
    Kessler HB, LoBuglio AF (1980) Interaction of monocytes with tumor cells coated with complement with or without antibody. Cell Immunol 49: 352Google Scholar
  17. 17.
    Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P (1979) Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5: 957Google Scholar
  18. 18.
    Liu AY, Robinson RA, Hellstrom KE, Murray ED, Chang CP, Hellstrom I (1987) Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 84: 3439Google Scholar
  19. 19.
    LoBuglio AF, Saleh M, Peterson L, Wheeler R, Carrano R, Huster W, Khazaeli MB (1986) Phase I clinical trial of CO17-1A monoclonal antibody. Hybridoma 5 (suppl 1): S117Google Scholar
  20. 20.
    Markwell MA, Fox CF (1978) Surface-specific iodination of membrane proteins of viruses and eucaryotic cells using 1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril. Biochemistry 17: 4807Google Scholar
  21. 21.
    McCabe RP, Peters LC, Haspel MV, Pomato N, Carrasquillo JA, Hanna MG (1988) Preclinical studies on the pharmacokinetic properties of human monoclonal antibodies to colorectal cancer and their use for detection of tumors. Cancer Res 48: 4348Google Scholar
  22. 22.
    Modolfsky PJ, Powe J, Mulheen CB, Sears HF, Hammond ND, Gatenby RA, Steplewski Z, Koprowski H (1983) Metastatic colon cancer detected with radiolabeled monoclonal antibody fragments. Radiology 149: 549Google Scholar
  23. 23.
    Morgan BP, Dankert JR, Esser AF (1987) Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol 138: 246Google Scholar
  24. 24.
    Morrison SL (1985) Transfectomas provide novel chimeric antibodies. Science 229: 1202Google Scholar
  25. 25.
    Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen binding domains with human constant region domains. Proc Natl Acad Sci USA 81: 6851Google Scholar
  26. 26.
    Ramos OF, Sarmay G, Klein E, Yefonof E, Gergely J (1985) Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum. Proc Natl Acad Sci USA 82: 5470Google Scholar
  27. 27.
    Sahagan BG, Dorai H, Saltzgaber-Muller J, Toneguzzo F, Guindon CA, Lilly SP, McDonald KW, Morrissey DV, Stone BA, Davis GL, McIntosh PK, Moore GP (1986) A genetically-engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen. J Immunol 137: 1066Google Scholar
  28. 28.
    Sears HF, Herlyn D, Steplewski Z, Koprowski H (1984) Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Mod 3: 138Google Scholar
  29. 29.
    Sears HF, Herlyn D, Steplewski Z, Koprowski H (1985) Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 45: 5910Google Scholar
  30. 30.
    Shaw DR, Khazaeli MB, Sun LK, Ghrayeb J, Daddona PE, McKinney S, LoBuglio AF (1987) Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen. J Immunol 138: 4534Google Scholar
  31. 31.
    Shaw DR, Harrison G, Sun LK, Sherman C, Ghrayeb J, McKinney S, Daddona PE, LoBuglio AF (1988) Human lymphocyte and monocyte lysis of tumor cells mediated by a mouse/human IgG1 chimeric monoclonal antibody. J Biol Response Mod 7: 204Google Scholar
  32. 32.
    Shawler DL, Bartholomew RM, Smith LM, Dillman RO (1985) Human immune response to multiple injections of murine monoclonal IgG. J Immunol 135: 1530Google Scholar
  33. 33.
    Steplewski Z, Lubeck MD, Koprowski H (1983) Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 221: 865Google Scholar
  34. 34.
    Steplewski Z, Sun LK, Sherman CW, Ghrayeb J, Daddona PE, Koprowski H (1988) Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with anti-tumor specificity. Proc Natl Acad Sci USA 85: 4852Google Scholar
  35. 35.
    Sun LK, Curtis P, Rakowicz-Szulczynska E, Ghrayeb J, Chang N, Morrison SL, Koprowsky H (1987) Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A. Proc Natl Acad Sci USA 84: 214Google Scholar
  36. 36.
    Taniyama T, Holden HT (1981) Cytotoxicity measured by the51Cr release assay. In: Manual of macrophage methodology. Marcel Dekker, New York, NY, p 323Google Scholar
  37. 37.
    Wiltrout RH, Taramelli D, Holden HT (1981) Indium-111 assay of macrophage-mediated cytolysis. In: Manual of macrophage methodology. Marcel Dekker, New York, NY, p 337Google Scholar
  38. 38.
    Yefenof E, Klein E, Yron I (1984) Contribution of activated C3 to lymphocyte-mediated target lysis: complement-dependent cellular cytotoxicity. Mol Immunol 21: 1211Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • William E. Fogler
    • 1
  • Lee K. Sun
    • 2
  • Mark R. Klinger
    • 1
  • John Ghrayeb
    • 2
  • Peter E. Daddona
    • 1
  1. 1.Department of Immunobiology, Research and DevelopmentCentocor Inc.MalvernUSA
  2. 2.Department of Molecular Biology, Research and DevelopmentCentocor Inc.MalvernUSA

Personalised recommendations